All Relations between dopaminergic and dopamine

Publication Sentence Publish Date Extraction Date Species
Achut P Silwal, H Peter L. Mode-Selective Raman Imaging of Dopamine-Human Dopamine Transporter Interaction in Live Cells. ACS chemical neuroscience. vol 9. issue 12. 2019-12-23. PMID:30024721. dopamine (da) is the catecholamine neurotransmitter which interacts with dopamine receptors (dars) to generate dopaminergic signals in the nervous system. 2019-12-23 2023-08-13 human
Khosro Jamebozorgi, Eskandar Taghizadeh, Daryoush Rostami, Hosein Pormasoumi, George E Barreto, Seyed Mohammad Gheibi Hayat, Amirhossein Sahebka. Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives. Molecular neurobiology. vol 56. issue 7. 2019-12-20. PMID:30397850. parkinson's disease is a neurodegenerative disorder accompanied by depletion of dopamine and loss of dopaminergic neurons in the brain that is believed to be responsible for the motor and non-motor symptoms in this disease. 2019-12-20 2023-08-13 human
Mareike Clos, Nico Bunzeck, Tobias Somme. Dopamine is a double-edged sword: dopaminergic modulation enhances memory retrieval performance but impairs metacognition. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 44. issue 3. 2019-12-18. PMID:30356095. dopamine is a double-edged sword: dopaminergic modulation enhances memory retrieval performance but impairs metacognition. 2019-12-18 2023-08-13 Not clear
Mareike Clos, Nico Bunzeck, Tobias Somme. Dopamine is a double-edged sword: dopaminergic modulation enhances memory retrieval performance but impairs metacognition. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 44. issue 3. 2019-12-18. PMID:30356095. while memory encoding and consolidation processes have been linked with dopaminergic signaling for a long time, the role of dopamine in episodic memory retrieval remained mostly unexplored. 2019-12-18 2023-08-13 Not clear
Imad Ghoraye. Idiopathic restless legs syndrome treatment: Progress and pitfalls? Advances in pharmacology (San Diego, Calif.). vol 84. 2019-12-18. PMID:31229172. although the dopaminergic and/or the iron breakdown homeostasis hypotheses are still considered to be the mainstay of the rls underlying mechanism, therapeutic intervention aiming to alleviate rls syndrome through dopamine agonists use and iron stores recovery failed so far to show short-term remarkable efficacy, and controlled trials to establish sustained long-term efficacy, tolerability and safety are lacking. 2019-12-18 2023-08-13 Not clear
Nayara S S Aquino, Ilona C Kokay, Carolina Thörn Perez, Sharon R Ladyman, Patricia C Henriques, Juneo F Silva, Christian Broberger, David R Grattan, Raphael E Szawk. Kisspeptin Stimulation of Prolactin Secretion Requires Kiss1 Receptor but Not in Tuberoinfundibular Dopaminergic Neurons. Endocrinology. vol 160. issue 3. 2019-12-09. PMID:30668693. thus, kisspeptin is likely to stimulate prolactin secretion via kiss1r in nondopaminergic neurons, whereas the colocalization of npffr1 and th suggests that pe dopaminergic neurons may play a role in the kisspeptin-induced inhibition of dopamine release. 2019-12-09 2023-08-13 mouse
Helena Vilaça-Faria, António J Salgado, Fábio G Teixeir. Mesenchymal Stem Cells-derived Exosomes: A New Possible Therapeutic Strategy for Parkinson's Disease? Cells. vol 8. issue 2. 2019-12-03. PMID:30717429. clinically, it is characterized by severe motor complications caused by a progressive degeneration of dopaminergic neurons (dan) and dopamine loss. 2019-12-03 2023-08-13 human
Dong Yun Lee, Minyoung Oh, Soo-Jong Kim, Jungsu S Oh, Sun Ju Chung, Jae Seung Ki. Bilirubin-Related Differential Striatal [18F]FP-CIT Uptake in Parkinson Disease. Clinical nuclear medicine. vol 44. issue 11. 2019-12-02. PMID:31490312. the objective of this study was to determine the relationship between basal serum levels of 2 molecules and dopaminergic deficit assessed by dopamine transporter imaging with f-fluorinated-n-3-fluoropropyl-2-β-carboxymethoxy-3-β-(4-iodophenyl)nortropane ([f]fp-cit) pet/ct in patients with early-stage drug-naive ipd. 2019-12-02 2023-08-13 Not clear
Andreas Weihofen, YuTing Liu, Joseph W Arndt, Christian Huy, Chao Quan, Benjamin A Smith, Jean-Luc Baeriswyl, Nicole Cavegn, Luzia Senn, Lihe Su, Galina Marsh, Pavan K Auluck, Fabio Montrasio, Roger M Nitsch, Warren D Hirst, Jesse M Cedarbaum, R Blake Pepinsky, Jan Grimm, Paul H Weinre. Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models. Neurobiology of disease. vol 124. 2019-11-29. PMID:30381260. in efficacy studies in three different mouse models with intracerebrally inoculated preformed α-syn fibrils, biib054 treatment attenuated the spreading of α-syn pathology, rescued motor impairments, and reduced the loss of dopamine transporter density in dopaminergic terminals in striatum. 2019-11-29 2023-08-13 mouse
E V Novosadova, E L Arsenyeva, S A Antonov, Y N Vanyushina, T V Malova, A A Komissarov, S N Illarioshkin, L G Khaspekov, L A Andreeva, N F Myasoedov, V Z Tarantul, I A Grivenniko. The Use of Human Induced Pluripotent Stem Cells for Testing Neuroprotective Activity of Pharmacological Compounds. Biochemistry. Biokhimiia. vol 84. issue 11. 2019-11-28. PMID:31760919. the endocannabinoid n-docosahexaenoyl dopamine exhibited the highest neuroprotective effect (~70%) in the differentiated cultures enriched with dopaminergic neurons; the effect of melanocortin semax was ~40%. 2019-11-28 2023-08-13 human
Nihar J Mehta, Praneet Kaur Marwah, David Nju. Are Proteinopathy and Oxidative Stress Two Sides of the Same Coin? Cells. vol 8. issue 1. 2019-11-27. PMID:30654525. many have suggested that dopamine oxidation products lead to oxidative stress accounting for the dopaminergic selectivity of the disease. 2019-11-27 2023-08-13 Not clear
Verónica Cabreira, Patrício Soares-da-Silva, João Massan. Contemporary Options for the Management of Motor Complications in Parkinson's Disease: Updated Clinical Review. Drugs. vol 79. issue 6. 2019-11-27. PMID:30905034. therapeutic strategies are grounded on modification of oral levodopa pharmacokinetics to extend levodopa benefit and development of new routes of drug delivery (e.g., levodopa/carbidopa intestinal gel infusion) or long-acting formulations of existing dopaminergic drugs to prolong the duration of striatal dopamine receptors stimulation. 2019-11-27 2023-08-13 Not clear
Margherita Torti, Daniele Bravi, Laura Vacca, Fabrizio Stocch. Are All Dopamine Agonists Essentially the Same? Drugs. vol 79. issue 7. 2019-11-27. PMID:30968290. in this article we discuss brain distribution of dopamine receptors and their role in each of the dopaminergic pathways, the pharmacological profile of non-ergoline das and class-related adverse effects, as reported from post-marketing studies. 2019-11-27 2023-08-13 human
Anthony Markha. Solriamfetol: First Global Approval. Drugs. vol 79. issue 7. 2019-11-27. PMID:31062265. norepinephrine and dopamine influence various physiologic functions, including sleep-wake regulation, and excessive sleepiness has been linked with dysregulation of dopaminergic and norepinephrine systems. 2019-11-27 2023-08-13 Not clear
Orhan Tansel Korkmaz, Neşe Tunçe. Advantages of Vasoactive Intestinal Peptide for the Future Treatment of Parkinson's Disease. Current pharmaceutical design. vol 24. issue 39. 2019-11-21. PMID:30636594. the characteristic symptoms of parkinson's disease, such as resting tremor, muscular rigidity, bradykinesia, postural instability and gait imbalance, are thought to be a result of the progressive degeneration of the dopaminergic neurons of the substantia nigra compacta, resulting in insufficient dopamine integrated signalling on gabaergic medium spiny neurons in the striatum. 2019-11-21 2023-08-13 Not clear
Smith, Hoepping, Johnson, Trzcinska, Kozikowsk. Dopaminergic agents for the treatment of cocaine abuse. Drug discovery today. vol 4. issue 7. 2019-11-20. PMID:10377510. because the pharmacological actions of cocaine stem laargely from its ability to block the dopamine transporter, many intervention strategies have focused on the dopaminergic pathway. 2019-11-20 2023-08-12 Not clear
Sawaguch. The role of D1-dopamine receptors in working memory-guided movements mediated by frontal cortical areas. Parkinsonism & related disorders. vol 7. issue 1. 2019-11-20. PMID:11008191. like the striatum, the frontal motor cortices receive dopaminergic fibers from midbrain dopamine cells and contain high levels of dopamine receptors. 2019-11-20 2023-08-12 monkey
b' Lled\\xc3\\xb. Dopamine agonists: the treatment for Parkinson\'s disease in the XXI century? Parkinsonism & related disorders. vol 7. issue 1. 2019-11-20. PMID:11008196.' moreover, as predicted by animal studies, on the long term, dopaminergic agonists induce significantly less motor complications than levodopa.in the last 2years, three new dopamine agonists have been launched, including ropinirole, pramipexole and cabergoline. 2019-11-20 2023-08-12 Not clear
Rinn. Treatment of early Parkinson's disease. Parkinsonism & related disorders. vol 7. issue 1. 2019-11-20. PMID:11008197. in this context, recent double-blind long-term studies have confirmed the earlier results, suggesting that it appears advisable to initiate dopaminergic treatment in early pd by initially using a dopamine agonist and by adding levodopa when the benefit is no longer adequate with dopamine agonist alone. 2019-11-20 2023-08-12 Not clear
Frim, Kan. Gene therapy for Parkinson's disease: review and update. Expert opinion on investigational drugs. vol 8. issue 10. 2019-11-20. PMID:11139810. current gene therapy models for pd are then described in two parts: genetic transfer of the biosynthetic enzymes for dopamine synthesis, and genetic transfer of the genes encoding neurotrophic factors protective for dopaminergic neurones. 2019-11-20 2023-08-12 Not clear